Treatment with cytokines

• US 20050260767A1
• Filed: 05/30/2003
• Published: 11/24/2005
• Est. Priority Date: 05/31/2002
• Status: Abandoned Application

• Current Assignee: Immunoclin Ltd. (Immunoclin Corp.)
• Original Assignee: Immunoclin Ltd. (Immunoclin Corp.)
• Inventors: Annoni, Giorgio, Clerici, Mario
• Application Number:
  US10/516,421
• Publication Number:
  US 20050260767A1
• Time in Patent Office: Days
• US Class Current: 436/518
• CPC Class Codes: A61K 38/19 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

An inflammatory process is suggested to be involved in the pathogenesis of Alzheimer'"'"'s disease (AD), a neurodegenerative disorder characterized by the presence of neuritic plaques within the cerebral cortex that are mainly composed of a small insoluble protein of 40-42 amino acids (amyloid protein). The biological correlates of this process are nevertheless not clear. Interleukin-10 (IL-10) is a cytokine that suppresses T lymphocytes and cell-mediated immunity in humans and mice and has potent anti-inflammatory properties. To verify if IL-10 production would be impaired in AD patients we stimulated PBMC of 47 patients and 25 age-matched healthy controls (HC) with a mitogen, a recall antigen or with amyloid peptides. IL-2 production was measured as well in the same cultural conditions. Results showed that amyloid-specific IL-10 generation is selectively and significantly reduced in AD patients (p=0.023). Analyses on the alleles of the IL-10 gene revealed that the genotype associated with high IL-10 production is extremely infrequent in AD individuals (2% vs. 28%). The presence of low/intermediate IL-10-producing genotypes (GCC/ATA; ATA/ATA) was associated with an earlier age at disease onset and (ACC/ACC; ACC/ATA) with an accelerated rate of disease progression. These data shed light on the biology of the inflammatory process involved in the pathogenesis of AD by showing that the presence of low-IL-10-allelic isoforms results in an amyloid-specific impairment of IL-10 production and is associated with the clinical severity of AD. These results lend support to the use of anti-inflammatory compounds in the therapy of this disease.

Claims

1. A method of determining the existence of or a predisposition to Alzheimer'"'"'s disease, autoimmune disease or other neurodegenerative diseases, the method comprising analysing a DNA bearing sample taken from a subject animal to determine the allelic variants present at one or more of the SNP loci at positions −

1082, −

819 and −

592 of the gene encoding IL-10.

2. A method according to claim 1, in which the genotype at all three positions −

1082, −

819 and −

592 is determined.

3. A method according to claim 1 which further comprises analysing the sample to determine the alleles present for the genes encoding IL-6 and Apo-E.

4. A method according to claim 3 which further comprises analysing the sample to determine the alleles present for the gene encoding IL-1.

5. A method of treating Alzheimer'"'"'s disease, autoimmune disease or other neurodegenerative disorder which comprises augmenting the function of a gene having one of the allelic polymorphisms of IL-10 shown in Table I.

7. A method according to claim 5 where the modulation of the function of the gene is by genetic therapy.

8. A method according to claim 5 where the modulation of the function of the gene is by pharmacological intervention.

9. A method according to claim 8 where the pharmacological intervention is using one or more compounds that enhance or inhibit antigen specific production of interleukin-10 and, optionally, one or more other cytokines.

10. A method according to claim 9, characterised in that the other cytokine is selected from the group consisting of interleukin-1 (α

or β

), interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-15, interleukin-16, interleukin-17, interferon-α

, interferon-β

, interferon-γ

, TNF-α

, TNF-β

, G-CSF, GM-CSF, M-LSF, and TGF-β

.

11. DNA fragments and cDNA fragments comprising the allelic polymorphs of Table I for use in the method of claim 7.

12. Use of the DNA or cDNA fragments of claim 11 in a method of screening compounds for the ability to modulate the allelic polymorphisms of Table I.

13. Use of the DNA or cDNA fragments of claim 11 in a method of screening compounds for the ability to modulate or prevent Alzheimer'"'"'s disease.

6. A method of treating Alzheimer'"'"'s disease, autoimmune disease or other neurodegenerative disorder which comprises decreasing the function of a gene having one of the allelic polymorphisms of IL-10 shown in Table I.

18. A method according to claim 6 where the modulation of the function of the gene is by genetic therapy.

19. A method according to claim 6 where the modulation of the function of the gene is by pharmacological intervention.

20. A method according to claim 19 where the pharmacological intervention is using one or more compounds that enhance or inhibit antigen specific production of interleukin-10 and, optionally, one or more other cytokines.

14. Use of cytokines in the preparation of a medicament for the treatment or prophylaxis of diseases which are not neoplastic.

15. Use according to claim 14, characterised in that the disease is a neurodegenerative disorder or an autoimmune disorder.

16. Use according to claim 14, characterised in that the use is for Alzheimer'"'"'s disease.

17. Use according to any one of claim 14, characterised in that the cytokine is selected from interleukin-1 (α

or β

), interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-15, interleukin-16, interleukin-17, interferon-α

, interferon-β

, interferon-γ

, TNF-α

, TNF-β

, G-CSF, GM-CSF, M-LSF, and TGF-β

.